CSF2 and neoplasm: The prolonged overall survival in stage III patients suggests that the presence of minimal/locoregional disease might facilitate the priming of anti-tumor immunity with GM-CSF secreting melanoma vaccines, which might be further intensified with the addition of immune checkpoint inhibitors.